

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM729026

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
INHIBRX, INC.		02/18/2022	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	OXFORD FINANCE LLC		
<b>Street Address:</b>	115 South Union Street		
<b>Internal Address:</b>	Suite 300		
<b>City:</b>	Alexandria		
<b>State/Country:</b>	VIRGINIA		
<b>Postal Code:</b>	22314		
<b>Entity Type:</b>	Limited Liability Company: DELAWARE		
<b>PROPERTY NUMBERS Total: 2</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	88595545	INHIBRX	
<b>Registration Number:</b>	6029997	CONTRA-MAB	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	6173106001		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	6173106000		
<b>Email:</b>	munozg@gtlaw.com		
<b>Correspondent Name:</b>	Greenberg Traurig, LLP		
<b>Address Line 1:</b>	One International Place		
<b>Address Line 2:</b>	Suite 2000		
<b>Address Line 4:</b>	Boston, MASSACHUSETTS 02110		
<b>ATTORNEY DOCKET NUMBER:</b>	138179.013400		
<b>NAME OF SUBMITTER:</b>	Eugenia A. Prezas		
<b>SIGNATURE:</b>	/Eugenia A. Prezas/		
<b>DATE SIGNED:</b>	05/19/2022		
<b>Total Attachments: 42</b>			
source=v 2_Oxford (Inhibrx) - IP Security Agreement (Executed Feb. 2022)#page1.tif			
source=v 2_Oxford (Inhibrx) - IP Security Agreement (Executed Feb. 2022)#page2.tif			



## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of February 18, 2022 by and between OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (“**Oxford**”), as collateral agent (in such capacity, “**Collateral Agent**”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender (each a “**Lender**” and collectively, the “**Lenders**”), INHIBRX, INC., a Delaware corporation with offices located at 11025 North Torrey Pines Road, Suite 200, La Jolla, CA 92037 (“**Grantor**”).

### RECITALS

A. Lenders have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the “**Loans**”) in the amounts and manner set forth in that certain Loan and Security Agreement by and between Collateral Agent, the Lenders and Grantor dated the Effective Date (as the same may be amended, modified or supplemented from time to time, the “**Loan Agreement**,” capitalized terms used herein are used as defined in the Loan Agreement). The Lenders are willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Collateral Agent, for the benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works to secure the obligations of Grantor under the Loan Agreement.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Loan Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

### AGREEMENT

To secure its obligations under the Loan Agreement and other Loan Documents (as defined in the Loan Agreement), Grantor grants and pledges to Collateral Agent, for the benefit of the Lenders, a security interest in all of Grantor’s right, title and interest in, to and under its Intellectual Property Collateral (including without limitation those Copyrights, Patents and Trademarks listed on Exhibits A, B and C hereto), and including without limitation all proceeds thereof (such as, by way of example but not by way of limitation, license royalties and proceeds of infringement suits), the right to sue for past, present and future infringements, all rights corresponding thereto throughout the world and all re-issues, divisions continuations, renewals, extensions and continuations-in-part thereof.

This security interest is granted in conjunction with the security interest granted to Collateral Agent, for the benefit of the Lenders, under the Loan Agreement. The rights and remedies of Collateral Agent with respect to the security interest granted hereby are in addition to those set forth in the Loan Agreement and the other Loan Documents, and those which are now or hereafter available to Collateral Agent, for the benefit of the Lenders, as a matter of law or equity. Each right, power and remedy of Collateral Agent provided for herein or in the Loan Agreement or any of the Loan Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Collateral Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Loan Agreement or any of the other Loan Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Lender, of any or all other rights, powers or remedies.

*[Balance of Page Intentionally Left Blank]*

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

**GRANTOR:**

Address of Grantor:  
11025 North Torrey Pines Road  
Suite 200  
La Jolla, CA 92037

Attn: Leah Pollema

INHIBRX, INC.

By: Kelly Deck  
Name: KELLY DECK  
Title: CFO

**COLLATERAL AGENT:**

Address of Lender:

115 South Union Street  
Suite 300  
Alexandria, VA 22314  
Attn: Legal Department

OXFORD FINANCE LLC

By: \_\_\_\_\_  
Name: \_\_\_\_\_  
Title: \_\_\_\_\_

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

**GRANTOR:**

Address of Grantor:  
11025 North Torrey Pines Road  
Suite 200  
La Jolla, CA 92037  
Attn: .....


INHIBRX, INC.

By: .....  
Name: .....  
Title: .....

**COLLATERAL AGENT:**

Address of Lender:  
  
115 South Union Street  
Suite 300  
Alexandria, VA 22314  
Attn: Legal Department

OXFORD FINANCE LLC

By:   
Name: Coleste H. Featherly  
Title: Senior Vice President

*[Signature Page to Intellectual Property Security Agreement]*

EXHIBIT A

Copyrights

None.

EXHIBIT B

Patents

See attached.

**EXHIBIT A**  
**COMPANY-OWNED PATENTS AND APPLICATIONS**

<b>WAP DOMAIN FUSION POLYPEPTIDES AND METHODS OF USE THEREOF</b>				
COOLEY				
<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
INHI-001/001US	US	Issued	13/536,987 28-Jun-12	8986688 24-Mar-15
INHI-001/C01US	US	Issued	14/616,351 28-Jun-12	9914765 13-Mar-18
INHI-001/N01MX	MX	Issued	MX/a/2013/015324 28-Jun-12	356433 29-May-18



**SERPIN FUSION PROTEINS AND METHODS OF USE THEREOF**

COOLEY

<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
INHI-002/001US	US	Issued	13/536,976 28-Jun-12	8,980,266 17-Mar-15
INHI-002/C01US	US	Issued	13/969,959 28-Jun-12	9,920,109 20-Mar-18
INHI-002/C02US	US	Issued	14/616,363 28-Jun-12	10,730,929 04-Aug-20
INHI-002/C03US	US	Issued	15/875,010 28-Jun-12	10,723,785 28-Jul-20
INHI-002/C05US	US	Pending	17/066,410 28-Jun-12	
INHI-002/C06US	US	Pending	17/315,511 27-Oct-14	
INHI-002/X01US	US	Issued	14/524,832 27-Oct-14	10,400,029 3-Sep-19
INHI-002/D01US	US	Issued	16/393,615 27-Oct-14	11,046,752 29-Jun-2021
INHI-002/D02US	US	Pending	16/908,271 28-Jun-12	
INHI-002/N01AU	AU	Issued	2012275287 28-Jun-12	2012275287 18-Jan-18
INHI-002/N02AU	AU	Issued	2015339507 27-Oct-15	2015339507 14-Oct-2021
INHI-002/D01AU	AU	Issued	2017279724 28-Jun-12	2017279724 27-Jun-19
INHI-002/D02AU	AU	Issued	2019202904 28-Jun-12	2019202904 22-April-21
INHI-002/D03AU	AU	Pending	2021202131 28-Jun-12	
INHI-002/D04AU	AU	Pending	2021240153 27-Oct-15	
INHI-002/N01BR	BR	Pending	BR 11 2013 033799-0 28-Jun-12	
INHI-002/N02BR	BR	Pending	BR112017008525 9 27-Oct-15	
INHI-002/D01BR	BR	Pending	BR122021005481-9 27-Oct-15	

INHI-002/N01CA	CA	Issued	2839619 28-Jun-12	2839619 16-Nov-21
INHI-002/D01CA	CA	Pending	TBD 28-Jun-12	
INHI-002/N02CN	CN	Pending	201580071331.7 27-Oct-15	
INHI-002/D01CN	CN	Pending	20190132137.5 28-Jun-12	
INHI-002/D02CN	CN	Pending	201910871347.6 28-Jun-12	
INHI-002/D03CN	CN	Pending	202111439584.9 27-Oct-15	
INHI-002/N01EG	EG	Pending	PCT 1977/2013 28-Jun-12	
INHI-002/N02EG	EG	Pending	PCT 678/2017 27-Oct-15	
INHI-002/N01EP Validated in: AL, AT, BA, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SK, SM, TR	EP	Issued	12804863.4 28-Jun-12	2726092 19-Jun-19
INHI-002/N02EP	EP	Pending	15854670.5 27-Oct-15	
INHI-002/D01EP	EP	Pending	19181040.7 28-Jun-12	
INHI-002/N01HK	HK	Issued	14111268.6 28-Jun-12	1197544 29-Apr-20
INHI-002/N02HK	HK	Pending	18103148.5 27-Oct-15	
INHI-002/D01HK	HK	Pending	42020002096.4 28-Jun-12	
INHI-002/D02HK	HK	Pending	42020007839.2 28-Jun-12	
INHI-002/N01IL	IL	Issued	230209 28-Jun-12	230209 1-Dec-2020

INHI-002/N02IL	IL	Pending	251799 27-Oct-15	
INHI-002/N03IL	IL	Pending	276534 28-Jun-12	
INHI-002/N01IN	IN	Issued	2441/MUMNP/2013 28-Jun-12	373030 27-Jul-21
INHI-002/N02IN	IN	Issued	201727015009 27-Oct-15	366213 6-May-21
INHI-002/N02JP	JP	Issued	2017-522654 27-Oct-15	6737781 20-Jul-2020
INHI-002/D01JP	JP	Issued	2017-134043 28-Jun-12	6674604 11-Mar-2020
INHI-002/D02JP	JP	Pending	2020-018783 28-Jun-12	
INHI-002/N01KR	KR	Issued	10-2014-7002346 28-Jun-12	10-2084944 28-Feb-2020
INHI-002/N02KR	KR	Pending	10-2017-7014414 27-Oct-15	
INHI-002/D01KR	KR	Issued	10-2020-7005907 28-Jun-12	10-2231139 17-Mar-21
INHI-002/D03KR	KR	Pending	10-2021-7043197 28-Jun-12	
INHI-002/N01MX	MX	Issued	MX/A/2013/015323 28-Jun-12	356517 1-Jun-18
INHI-002/D01MX	MX	Issued	MX/A/2018/006710 28-Jun-12	381183 6-Apr-21
INHI-002/N02MX	MX	Pending	MX/A/2017/005467 27-Oct-15	
INHI-002/D02MX	MX	Pending	MX/A/2021/003791 28-Jun-12	
INHI-002/D03MX	MX	Pending	MX/A/2021/012047 28-Jun-12	
INHI-002/N01NZ	NZ	Issued	619023 28-Jun-12	619023 3-Nov-15
INHI-002/D02NZ	NZ	Pending	727846 28-Jun-12	
INHI-002/N02NZ	NZ	Pending	731223 27-Oct-15	
INHI-002/D04NZ	NZ	Pending	769391 27-Oct-15	

INHI-002/D03NZ	NZ	Pending	744257 28-Jun-12	
INHI-002/N01RU	RU	Issued	2014102583 28-Jun-12	2642310 24-Jan-18
INHI-002/N02RU	RU	Issued	2017118325 27-Oct-15	2746550 15-Apr-21
INHI-002/D01RU	RU	Issued	2017145308 28-Jun-12	2698655 28-Aug-19
INHI-002/D02RU	RU	Issued	2019121798 28-Jun-12	2728861 31-Jul-20
INHI-002/D03RU	RU	Issued	2019121797 28-Jun-12	2727452 21-Jul-20
INHI-002/D04RU	RU	Pending	2020124172 28-Jun-12	
INHI-002/D02SG	SG	Pending	10201811256Q 28-Jun-12	
INHI-002/D03SG	SG	Pending	10201903142R 27-Oct-15	
INHI-002/N01UA	UA	Issued	a 2014 00709 28-Jun-12	124083 22-Jul-21
INHI-002/N02UA	UA	Pending	a 2017 05128 27-Oct-15	
INHI-002/D01UA	UA	Pending	a 2019 02302 28-Jun-12	

**PD-1 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOF**

COOLEY

<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./Issue date:</b>
INHI-041/D01GC	GCC	Pending	41515 14-Jul-2019	
INHI-041/001TW	TW	Pending	108136936 14-Oct-19	
INHI-041/001US	US	Issued	16/600,298 11-Oct-19	11,208,485 28-Dec-21
INHI-041/D01US	US	Pending	17/524,016 11-Oct-19	
INHI-041/N01AU	AU	Pending	2019356573 11-Oct-19	
INHI-041/N01CA	CA	Pending	3115285 11-Oct-19	
INHI-041/N01CN	CN	Pending	201980082154.0 11-Oct-19	
INHI-041/N01EP	EP	Pending	19797897.6 11-Oct-19	
INHI-041/N01JP	JP	Pending	2021-519705 11-Oct-19	

<b>NON-IMMUNOGENIC SINGLE DOMAIN ANTIBODIES</b>				
COOLEY				
<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
INHI-018/001US 01202-0001-00US	US	Issued	15/003,234 21-Jan-16	10,526,397 7-Jan-20
INHI-018/D01US	US	Pending	16/685,087 21-Jan-16	
INHI-018/N01AU	AU	Issued	2016209247 21-Jan-16	2016209247 10-Jun-2021
INHI-018/D01AU	AU	Pending	2021202314/ 16-Apr-2021	
INHI-018/N01CA	CA	Pending	2974192 21-Jan-16	
INHI-018/N01CN	CN	Pending	201680017175 21-Jan-16	
INHI-018/N01EP	EP	Pending	16740748.5 21-Jan-16	
INHI-018/N01HK	HK	Pending	18106152.1 21-Jan-16	
INHI-018/N01JP	JP	Pending	2017-538374 21-Jan-16	
INHI-018/D01JP	JP	Pending	TBD 21-Jan-16	

**TYPE III SECRETION SYSTEMS TARGETING MOLECULES**

MCNEILL BAUR

<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
INHI-020/001US 01202-0002-00US	US	Issued	15/144,470 2-May-16	10,344,078 9-Jul-19
INHI-020/002US 01202-0002-01US	US	Issued	16/419,677 1-May-15	10,745,466 18-Aug-20
INHI-020/N01AU 01202-0002-00AU	AU	Issued	2016257751 2-May-16	2016257751 6-May-2021
INHI-020/N01BR 01202-0002-00BR	Brazil	Pending	BR112017023378-9 2-May-16	
INHI-020/N01CA 01202-0002-00CA	CA	Pending	2984628 2-May-16	
INHI-020/N01CN 01202-0002-00CN	CN	Pending	201680038692.6 2-May-16	
INHI-020/N01EP 01202-0002-00EP Validated in: CH, DE, FR, GB, IT, NL	EP	Issued	16789896.4 2-May-16	3288974 4-Nov-20
INHI-020/N01HK 01202-0002-00HK	HK	Issued	18110279.1 2-May-16	1250991 28-May2021
INHI-020/N01IL 01202-0002-00IL	IL	Pending	255329 2-May-16	
INHI-020/N01IN 01202-0002-00IN	IN	Pending	201717042342 2-May-16	
INHI-020/N01JP 01202-0002-00JP	JP	Pending	2017-557060 2-May-16	
INHI-020/N01KR 01202-0002-00KR	KR	Pending	10-2017-7034743 2-May-16	
INHI-020/N01MX 01202-0002-00MX	MX	Pending	MX/A/2017/014002 2-May-16	
INHI-020/N01NZ 01202-0002-00NZ	NZ	Pending	736776 2-May-16	
01202-0002-01NZ	NZ	Pending	774893 2-May-16	
INHI-020/N01RU 01202-0002-00RU	RU	Pending	2017141738 2-May-16	

INHI-020/N01ZA 01202-0002-00ZA	ZA	Pending	2017/07404 2-May-16	
-----------------------------------	----	---------	------------------------	--



**MULTIVALENT AND MULTISPECIFIC DR5-BINDING FUSION PROTEINS**

MCNEILL BAUR

<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
INHI-021/US001 01202-0003-00US	US	Issued	15/213,296 18-Jul-16	10,308,720 4-Jun-19
INHI-021/US002 01202-0003-01US	US	Issued	16/387,754 18-Jul-16	11,117,973 14-Sep-21
01202-0003-02US	US	Pending	17/394,900 18-Jul-16	
INHI-021-AU 01202-0003-00AU	AU	Pending	2016291701 18-Jul-16	
INHI-021-BR 01202-0003-00BR	BR	Pending	11 2018 000584-3 18-Jul-16	
INHI-021-CA 01202-0003-00CA	CA	Pending	2991634 18-Jul-16	
INHI-021-CN 01202-0003-00CN	CN	Pending	201680041274.2 18-Jul-16	
01202-0003-01CN	CN	Pending	202111039963.9 18-Jul-16	
INHI-021-EP 01202-0003-00EP Validated in: AL, AT, BA, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR	EP	Issued	16825315.1 18-Jul-16	3322734 9-Sep-20
01202-0003-01EP	EP	Pending	20189995.2 18-Jul-16	
INHI-021-HK 01202-0003-00HK	HK	Issued	18113517.7 18-Jul-16	1254433 23-Apr-2021
01202-0003-01HK	HK	Pending	42021038711 18-Jul-16	
INHI-021-ID 01202-0003-00ID	ID	Pending	PID201800330 18-Jul-16	

01202-0003-01ID	ID	Pending	P00202010721 18-Jul-16	
INHI-021-IL 01202-0003-00IL	IL	Pending	256772 18-Jul-16	
INHI-021-IN 01202-0003-00IN	IN	Pending	201817001451.0 18-Jul-16	
01202-0003-01IN	IN	Pending	202118055765.0 18-Jul-16	
INHI-021-JP 01202-0003-00JP	JP	Issued	2018-501345 18-Jul-16	6807606 10-Dec-20
01202-0003-01JP	JP	Pending	2020-196358 18-Jul-16	
INHI-021-KR 01202-0003-00KR	KR	Pending	10-2018-7000975 18-Jul-16	
INHI-021-MX 01202-0003-00MX	MX	Pending	MX/A/2018/000523 18-Jul-16	
INHI-021-NZ 01202-0003-00NZ	NZ	Pending	738850 18-Jul-16	
01202-0003-01NZ	NZ	Pending	777930 18-Jul-16	
INHI-021-RU 01202-0003-00RU	RU	Issued	2018102803 18-Jul-16	2748620 28-May-2021
01202-0003-01RU	RU	Pending	2021111382 18-Jul-16	
INHI-021-SG 01202-0003-00SG	SG	Issued	11201800223W 18-Jul-16	11201800223W 24-Aug-20
01202-0003-01SG	SG	Pending	10201912410T 18-Jul-16	
INHI-021-TH 01202-0003-00TH	TH	Pending	1801000218 18-Jul-16	
INHI-021-ZA 01202-0003-00ZA	ZA	Issued	2018/00238 18-Jul-16	2018/00238 28-Jul-21

**MULTIVALENT AND MULTISPECIFIC GITR-BINDING FUSION PROTEINS**

COOLEY

<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
INHI-022/001US	US	Issued	15/217,754 22-Jul-16	10,093,742 10-Sep-18
INHI-022/C02US	US	Issued	16/119,950 31-Aug-18	10,844,129 24-Nov-20
INHI-022/N01AR	AR	Pending	P20160102253 25-Jul-16	
INHI-022/N01AU	AU	Issued	2016297249 22-Jul-16	2016297249 25-Feb-21
INHI-022/N01BR	BR	Pending	BR1120180011614 22-Jul-16	
INHI-022/N01CA	CA	Pending	2992298 22-Jul-16	
INHI-022/N01CN	CN	Pending	201680055497.4 22-Jul-16	
INHI-022/N01EP	EP	Pending	16828658.1 22-Jul-16	
INHI-022/N01HK	HK	Pending	18114788.7 22-Jul-16	
INHI-022/N01IL	IL	Pending	257030 22-Jul-16	
INHI-022/N01IN	IN	Pending	201817002562 22-Jul-16	
INHI-022/N01JP	JP	Issued	2018-523387 22-Jul-16	6913682 14-Jul-2021
INHI-022/N01KR	KR	Pending	10-2018-7004964 22-Jul-16	
INHI-022/N01MX	MX	Pending	MX/A/2018/000948 22-Jul-16	
INHI-022/N01NZ	NZ	Pending	739130 22-Jul-16	
INHI-022/D01NZ	NZ	Pending	762978 22-Jul-16	
INHI-022/N01RU	RU	Issued	2018106452 22-Jul-16	2753439 16-Aug-2021

INHI-022/N01SG	SG	Pending	11201800473Y 22-Jul-16	
INHI-022/D01SG	SG	Pending	10201913807Q 22-Jul-16	
INHI-022/001TW	TW	Issued	105123463 25-Jul-16	I745296 11-Nov-21
INHI-022/N01ZA	ZA	Issued	2018/00410 22-Jul-16	2018/00410 28-Jul-2021

**MULTIVALENT AND MULTISPECIFIC OX40-BINDING FUSION PROTEINS**

MCNEILL BAUR

<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
01202-0004-01US	US	Issued	16/295,332 11-Jan-17	11,117,972 14-Sep-21
01202-0004-02US	US	Pending	17/398,851 11-Jan-17	
INHI-023/001AU 01202-0004-00AU	AU	Pending	2017207318 11-Jan-17	
INHI-023/001BR 01202-0004-00BR	BR	Pending	BR112018013911-4 11-Jan-17	
INHI-023/001CA 01202-0004-00CA	CA	Pending	3,009,075 11-Jan-17	
INHI-023/001CN 01202-0004-00CN	CN	Pending	201780005939.9 11-Jan-17	
INHI-023/001EP 01202-0004-00EP	EP	Pending	17738885.7 11-Jan-17	
01202-0004-00HK	HK	Pending	19121596.1 11-Jan-17	
INHI-023/001ID 01202-0004-00ID	ID	Pending	201804576 11-Jan-17	
INHI-023/001IL 01202-0004-00IL	IL	Pending	260531 11-Jan-17	
INHI-023/001IN 01202-0004-00IN	IN	Pending	201817024025 11-Jan-17	
INHI-023/001JP 01202-0004-00JP	JP	Pending	2018-535298 11-Jan-17	
INHI-023/001KR 01202-0004-00KR	KR	Pending	10-2018-7022337 11-Jan-17	
INHI-023/001MX 01202-0004-00MX	MX	Pending	MX/A/2018/008310 11-Jan-17	
INHI-023/001NZ 01202-0004-00NZ	NZ	Pending	743731 11-Jan-17	
01202-0004-01NZ	NZ	Pending	783287 11-Jan-17	
INHI-023/001RU 01202-0004-00RU	RU	Pending	2018128629 11-Jan-17	
INHI-023/001SG 01202-0004-00SG	SG	Pending	11201805422W 11-Jan-17	
INHI-023/001TH 01202-0004-00TH	TH	Pending	1801004046 11-Jan-17	

INHI-023/001ZA 01202-0004-00ZA	ZA	Pending	2018/04103 11-Jan-17	
-----------------------------------	----	---------	-------------------------	--

**MULTIVALENT AND MULTISPECIFIC 41BB-BINDING FUSION PROTEINS**

MCNEILL BAUR

<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
INHI-027/001US 01202-0005-00US	US	Issued	15/404,016 11-Jan-17	10,501,551 10-Dec-19
01202-0005-01US	US	Pending	16/601,825 11-Jan-17	
INHI-027/N01AU 01202-0005- 00NAU	AU	Pending	2017207742 11-Jan-17	
INHI-027/N01BR 01202-0005-00BR	BR	Pending	BR112018013677-8 11-Jan-17	
INHI-027/N01CA 01202-0005-00CA	CA	Pending	3009661 11-Jan-17	
INHI-027/N01CN 01202-0005-00CN	CN	Pending	201780005185.7 11-Jan-17	
INHI-027/N01EP 01202-0005-00EP	EP	Pending	17738869.1 11-Jan-17	
INHI-027/N01HK 01202-0005-00HK	HK	Pending	19121248.9 11-Jan-17	
INHI-027/N01ID 01202-0005-00ID	ID	Pending	PID201804675 11-Jan-17	
01202-0005-01ID	ID	Pending	P00202104385 11-Jan-17	
INHI-027/N01IL 01202-0005-00IL	IL	Pending	260530 11-Jan-17	
INHI-027/N01IN 01202-0005-00IN	IN	Pending	201817024028 11-Jan-17	
INHI-027/N01JP 01202-0005-00JP	JP	Pending	2018-535301 11-Jan-17	
INHI-027/N01KR 01202-0005-00KR	KR	Pending	10-2018-7022340 11-Jan-17	
INHI-027/N01MX 01202-0005-00MX	MX	Pending	MX/A/2018/008308 11-Jan-17	
INHI-027/N01NZ 01202-0005-00NZ	NZ	Pending	743793 11-Jan-17	
01202-0005-01NZ	NZ	Pending	783324 11-Jan-17	
01202-0005-02NZ	NZ	Pending	783320 11-Jan-17	
INHI-027/N01RU 01202-0005-00RU	RU	Pending	2018128601 11-Jan-17	

INHI-027/N01SG 01202-0005-00SG	SG	Pending	11201805532X 11-Jan-17	
01202-0005-01SG	SG	Pending	10201912405T 11-Jan-17	
INHI-027/N01TH 01202-0005-00TH	TH	Pending	1801003929 11-Jan-17	
INHI-027/N01ZA	ZA	Pending	2018/04390 11-Jan-17	

<b>MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND METHODS OF USING THE SAME</b>				
<i>MoFo (POTTER/RICE)</i>				
<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
74495-20001.00	US	Pending	15/951,137 11-Apr-18	
74495-20001.41	TW	Pending	107112430 11-Apr-18	
74495-20001.42	AU	Pending	2018250641 11-Apr-18	
74495-20001.43	BR	Pending	BR112019020940-9 11-Apr-18	
74495-20001.44	CA	Pending	3,058,477 11-Apr-18	
74495-20001.45	CN	Pending	201880038526.5 11-Apr-18	
74495-20001.46	EP	Pending	18721596.7 11-Apr-18	
74495-20001.47	IN	Pending	201917041454 11-Apr-18	
74495-20001.48	IL	Pending	269826 11-Apr-18	
74495-20001.49	JP	Pending	2019-555817 11-Apr-18	
74495-20001.50	KR	Pending	10-2019-7033354 11-Apr-18	
74495-20001.51	MX	Pending	MX/a/2019/012198 11-Apr-18	
74495-20001.52	NZ	Pending	758264 11-Apr-18	



74495-20001.53	RU	Pending	2019135842 11-Apr-18	
74495-20001.54	SG	Pending	11201909160W 11-Apr-18	
74495-20001.55	ZA	Pending	2019/06795 11-Apr-18	
74495-20001.56	ID	Pending	P00201908881 11-Apr-18	
74495-20001.57	MY	Pending	PI2019005867 11-Apr-18	
74495-20001.58	PH	Pending	1-2019-502303 11-Apr-18	
74495-20001.59	SA	Pending	519410284 11-Apr-18	
74495-20001.60	HK	Pending	62020013353.1 11-Apr-18	
74495-20001.61	HK	Pending	62020013505.6 11-Apr-18	

**MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND RELATED METHODS AND USES**

MoFo (POTTER/RICE)

<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
74495-20002.00	US	Pending	16/380,963 10-Apr-19	
74495-20002.41	TW	Pending	108112538 10-Apr-19	
74495-20002.42	AU	Pending	2019251488 10-Apr-19	
74495-20002.43	BR	Pending	BR112020020604-0 10-Apr-19	
74495-20002.44	CA	Pending	3,096,123 10-Apr-19	
74495-20002.45	CN	Pending	201980037529.1 10-Apr-19	
74495-20002.46	EP	Pending	19719134.9 10-Apr-19	
74495-20002.56	HK	Pending	62021034946.5 10-Apr-2019	
74495-20002.47	IN	Pending	202017043715 10-Apr-19	
74495-20002.48	IL	Pending	277863 10-Apr-19	
74495-20002.49	JP	Pending	2020-555516 10-Apr-19	
74495-20002.50	KR	Pending	10-2020-7032497 10-Apr-19	
74495-20002.51	MX	Pending	MX/a/2020/010638 10-Apr-19	
74495-20002.52	NZ	Pending	768465 10-Apr-19	
74495-20002.53	SG	Pending	11202009804R 10-Apr-19	
74495-20002.54	ZA	Pending	2020/06172 10-Apr-19	

**B7H3 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOF***MoFo (POTTER/RICE)*

<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
74495-20004.00	US	Pending	17/283,902 09-Oct-2019	
74495-20004.41	TW	Pending	108136773 09-Oct-2019	
74495-20004.42	CA	Pending	3,115,082 09-Oct-2019	
74495-20004.43	CN	Pending	201980082130.5 09-Oct-2019	
74495-20004.44	EP	Pending	19791442.7 09-Oct-2019	
74495-20004.45	JP	Pending	2021-520917 09-Oct-2019	

**5T4 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOF***MoFo (POTTER/RICE)*

<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
74495-20005.00	US	Pending	17/283,830 09-Oct-2019	
74495-20005.41	TW	Pending	108136772 09-Oct-2019	
74495-20005.42	CA	Pending	3,114,693 09-Oct-2019	
74495-20005.43	CN	Pending	201980080771.7 09-Oct-2019	
74495-20005.44	EP	Pending	19794391.3 09-Oct-2019	
74495-20005.45	JP	Pending	2021-520187 09-Oct-2019	

**DLL3 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOF**

MoFo (POTTER/RICE)

<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
74495-20006.00	US	Pending	17/283,903 09-Oct-2019	
74495-20006.41	TW	Pending	108136743 09-Oct-2019	
74495-20006.42	CA	Pending	3,115,089 09-Oct-2019	
74495-20006.43	CN	Pending	201980082197.9 09-Oct-2019	
74495-20006.44	EP	Pending	19794390.5 09-Oct-2019	
74495-20006.45	JP	Pending	2021-520217 09-Oct-2019	

**MULTISPECIFIC POLYPEPTIDE CONSTRUCTS CONTAINING A CONSTRAINED CD3 BINDING DOMAIN AND A RECEPTOR BINDING REGION AND METHODS OF USING THE SAME**

MoFo (POTTER/RICE)

<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
74495-20008.00	US	Pending	16/520,293 23-Jul-19	
74495-20008.40	PCT	Pending	PCT/US2019/043115 23-Jul-19	
74495-20008.41	TW	Pending	108126062 23-Jul-19	
74495-20008.42	CA	Pending	3105891 07-23-2019	
74495-20008.43	CN	Pending	201980061774.6 23-Jul-2019	
74495-20008.44	EP	Pending	19749970.0 07-23-2019	
74495-20008.45	JP	Pending	2021-503831 07-23-2019	

74495-20008.46	HK	Pending	62021042243.7 23-Jul-2019	
----------------	----	---------	------------------------------	--

**CD28 SINGLE DOMAIN ANTIBODIES AND MULTIVALENT AND MULTISPECIFIC CONSTRUCTS THEREOF**

*MoFo (POTTER/RICE)*

<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
74495-20015.40	PCT	Pending	PCT/US2021/015590 01-28-2021	

**POLYPEPTIDES COMPRISING MODIFIED IL-2 POLYPEPTIDES AND USES THEREOF**

*MCNEILL BAUR*

<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
01202-0011-00US	US	Pending	17/418,458 6-Jan-20	
01202-0011-00AU	AU	Pending	2020206672 6-Jan-20	
01202-0011-00AR	AR	Pending	P200100028 6-Jan-20	
01202-0011-00BR	BR	Pending	BR112021012294-0 6-Jan-20	
01202-0011-00CA	CA	Pending	3125529 6-Jan-20	
01202-0011-00CL	CL	Pending	1779-2021 6-Jan-20	
01202-0011-00CN	CN	Pending	202080018011.6 6-Jan-20	
01202-0011-00EP	EP	Pending	20702547.9 6-Jan-20	
01202-0011-00GC	GCC	Pending	2020-38967 6-Jan-20	
01202-0011-00IL	IL	Pending	284633 6-Jan-20	
01202-0011-00IN	IN	Pending	202117028056.0 6-Jan-20	

01202-0011-00JP	JP	Pending	TBD 6-Jan-20	
01202-0011-00KR	KR	Pending	10-2021-7024431 6-Jan-20	
01202-0011-00MX	MX	Pending	MX/a/2021/008147 6-Jan-20	
01202-0011-00MY	MY	Pending	PI2021003501 6-Jan-20	
01202-0011-00NZ	NZ	Pending	777431 6-Jan-20	
01202-0011-00SG	SG	Pending	11202106700W 6-Jan-20	
01202-0011-00TW	TW	Pending	109100336 6-Jan-20	
01202-0011-00ZA	ZA	Pending	2021/04475 6-Jan-20	

#### OX40-BINDING POLYPEPTIDES AND USES THEREOF

MCNEILL BAUR

Docket No.	Country	Status	Serial No./ Filing Date	Patent No./ Issue Date
01202-0014-00US	US	Pending	16/538,216 12-Aug-19	
01202-0014-00AR	AR	Pending	P190102293 12-Aug-19	
01202-0014-00GC	GCC	Pending	38123 18-Aug-19	
01202-0014-00TW	TW	Pending	108128661 12-Aug-19	
01202-0014-00AU	AU	Pending	2019321490 12-Aug-19	
01202-0014-00BR	BR	Pending	BR112021002164-7 12-Aug-19	
01202-0014-00CA	CA	Pending	3107767 12-Aug-19	
01202-0014-00CL	CL	Pending	0347-2021 12-Aug-19	
01202-0014-00CN	CN	Pending	201980054189.3 12-Aug-19	

01202-0014-00EP	EP	Pending	19762513 12-Aug-2019	
01202-0014-00HK-CN	HK	Pending	62021039062 12-Aug-19	
01202-0014-00HK-EP	HK	Pending	62021039128 12-Aug-19	
01202-0014-00ID	ID	Pending	P00202101153 12-Aug-19	
01202-0014-00IL	IL	Pending	280808 12-Aug-19	
01202-0014-00IN	IN	Pending	202117006098.0 12-Aug-19	
01202-0014-00JP	JP	Pending	2021-506977 12-Aug-19	
01202-0014-00KR	KR	Pending	10-2021-7006759 12-Aug-2019	
01202-0014-00MX	MX	Pending	MX/A/2021/001703 12-Aug-19	
01202-0014-00MY	MY	Pending	PI2021000597 12-Aug-19	
01202-0014-00NZ	NZ	Pending	772290 12-Aug-19	
01202-0014-00PH	PH	Pending	1-2021-550289 12-Aug-19	
01202-0014-00RU	RU	Pending	2021106197 12-Aug-2019	
01202-0014-00SG	SG	Pending	11202101173T 12-Aug-19	
01202-0014-00TH	TH	Pending	2101000677 12-Aug-19	
01202-0014-00VN	VN	Pending	1-2021-01221 12-Aug-19	
01202-0014-00ZA	ZA	Pending	2021/00634 12-Aug-19	

**CD123-BINDING POLYPEPTIDES AND USES THEREOF**

MCNEILL BAUR

<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
01202-0021-00US	US	Pending	16/864,478 1-May-20	
01202-0021-00AU	AU	Pending	2020269268 1-May-20	
01202-0021-00CA	CA	Pending	3139061 1-May-20	
01202-0021-00CN	CN	Pending	202080048186.1 1-May-20	
01202-0021-00EP	EP	Pending	20726662.8 1-May-20	
01202-0021-00JP	JP	Pending	2021-564745 1-May-20	



**CD33-BINDING POLYPEPTIDES AND USES THEREOF**

MCNEILL BAUR

<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
01202-0022-00US	US	Pending	16/864,480 1-May-20	
01202-0022-00AU	AU	Pending	2020268827 1-May-20	
01202-0022-00BR	BR	Pending	BR112021021048-2 1-May-20	
01202-0022-00CA	CA	Pending	3138969 1-May-20	
01202-0022-00CN	CN	Pending	TBA 1-May-20	
01202-0022-00EA	EA	Pending	202192997 1-May-20	
01202-0022-00EP	EP	Pending	20730151.6 1-May-20	
01202-0022-00ID	ID	Pending	P00202108998 1-May-20	
01202-0022-00IL	IL	Pending	287782 1-May-20	
01202-0022-00IN	IN	Pending	202117050146.0 1-May-20	
01202-0022-00JP	JP	Pending	2021-564746 1-May-20	
01202-0022-00KR	KR	Pending	10-2021-7039701 1-May-20	
01202-0022-00MX	MX	Pending	MX/A/2021/013416 1-May-20	
01202-0022-00SG	SG	Pending	11202111711P 1-May-20	

**CLEC12A BINDING POLYPEPTIDES AND USES THEREOF**

MCNEILL BAUR

<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
01202-0023-00US	US	Pending	16/864,481 1-May-20	
01202-0023-00AU	AU	Pending	TBA 1-May-20	
01202-0023-00BR	BR	Pending	BR112021020999-9 1-May-20	
01202-0023-00CA	CA	Pending	3138972 1-May-20	
01202-0023-00CN	CN	Pending	TBA 1-May-20	
01202-0023-00EA	EA	Pending	202192998 1-May-20	
01202-0023-00EP	EP	Pending	20727504.1 1-May-20	
01202-0023-00ID	ID	Pending	P00202109000 1-May-20	
01202-0023-00IL	IL	Pending	287781 1-May-20	
01202-0023-00IN	IN	Pending	202117050659.0 1-May-20	
01202-0023-00JP	JP	Pending	2021-564747 1-May-20	
01202-0023-00KR	KR	Pending	10-2021-7039702 1-May-20	
01202-0023-00MX	MX	Pending	MX/A/2021/013417 1-May-20	
01202-0023-00SG	SG	Pending	11202111731W 1-May-20	

### **CD123 TARGETED IMMUNOTHERAPIES**

MCNEILL BAUR

<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
01202-0024-00US-M	US	Pending	17/608,739 7-May-20	
01202-0024-00PCT-M	PCT	Pending	PCT/US20/31794 7-May-20	

01202-0024-00AU-M	AU	Pending	2020267559 7-May-20	
-------------------	----	---------	------------------------	--

### CD-33 TARGETED IMMUNOTHERAPIES

MCNEILL BAUR

Docket No.	Country	Status	Serial No./ Filing Date	Patent No./ Issue Date
01202-0025-00US-M	US	Pending	17/608,743 7-May-20	
01202-0025-00PCT-M	PCT	Pending	17/608,743 7-May-20	
01202-0025-00AU-M	AU	Pending	2020268379 7-May-20	
01202-0025-00JP-M	JP	Pending	2021-566152 7-May-20	
01202-0025-00MX-M	MX	Pending	MX/A/2021/013591 7-May-20	

### CLL-1 TARGETED IMMUNOTHERAPIES

MCNEILL BAUR

Docket No.	Country	Status	Serial No./ Filing Date	Patent No./ Issue Date
01202-0026-00US-M	US	Pending	17/608,738 7-May-20	
01202-0026-00PCT-M	PCT	Pending	PCT/US20/31781 7-May-20	
01202-0026-00AU-M	AU	Pending	2020267639 7-May-20	
01202-0026-00BR-M	BR	Pending	BR1120210223657 7-May-20	
01202-0026-00EA-M	EA	Pending	202193071 7-May-20	
01202-0026-00EP-M	EP	Pending	20801987.7 7-May-20	
01202-0026-00IL-M	IL	Pending	287769 7-May-20	

01202-0026-00IN-M	IN	Pending	202117052262.0 7-May-20	
01202-0026-00JP-M	JP	Pending	2021-566149 7-May-20	
01202-0026-00KR-M	KR	Pending	10-2021-7039632 7-May-20	
01202-0026-00MX-M	MX	Pending	MX/A/2021/013590 7-May-20	

**CANINE PD-1-BINDING POLYPEPTIDES AND USES THEREOF**

MCNEILL BAUR

<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
01202-0016-00PCT	PCT	Pending	PCT/US2021/030476 3-May-21	

**POLYPEPTIDES COMPRISING MODIFIED IL-2 POLYPEPTIDES AND USES THEREOF**

MCNEILL BAUR

<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
01202-0040-00PCT	PCT	Pending	PCT/US2021/040061 1-Jul-21	
01202-0040-00AR	AR	Pending	210101857 1-Jul-21	
01202-0040-00TW	TW	Pending	110124255 1-Jul-21	

**AML TARGETED IMMUNOTHERAPIES**

MCNEILL BAUR

<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
01202-0047- 00PCT-M	PCT	Pending	PCT/US2021/058562 9-Nov-21	

**CD33 TARGETED IMMUNOTHERAPIES**

MCNEILL BAUR

<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
01202-0048- 00PCT-M	PCT	Pending	PCT/US2021/058559 9-Nov-21	

**PROVISIONAL APPLICATIONS**

<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Title</b>
MCNEILL BAUR				
01202-0031-61US	US	Pending	63/223,786 20-Jul-21	CD8-BINDING POLYPEPTIDES AND USES THEREOF
01202-0031-62US	US	Pending	63/288,111 10-Dec-21	
01202-0045-61US	US	Pending	63/223,798 20-Jul-21	CD8-TARGETED MODIFIED IL-2 AND USES THEREOF
01202-0045-62US	US	Pending	63/288,113 10-Dec-21	
01202-0048-60US- M	US	Pending	63/111,280 9-Nov-20	CD33 TARGETED IMMUNOTHERAPIES
01202-0049-60US	US	Pending	63/151,131 19-Feb-21	FORMULATIONS OF DR5 BINDING POLYPEPTIDES
01202-0050-60US	US	Pending	63/215,018 25-Jun-21	IGE BINDING POLYPEPTIDES AND USES THEREOF

01202-0029-60US	US	Pending	63/238,429 30-Aug-21	
01202-0051-60US	US	Pending	63/238,431 30-Aug-21	

**EXHIBIT B**  
OUT-LICENSED PATENTS AND APPLICATIONS

<b>CD47 ANTIBODIES AND METHODS OF USE THEREOF</b>				
<i>MoFo (POON/POLIZZI/YOU)</i>				
<b>Docket No.</b>	<b>Country</b>	<b>Status</b>	<b>Serial No./ Filing Date</b>	<b>Patent No./ Issue Date</b>
INBRX001-US	US	Issued	13/761,087 6-Feb-2013	9,045,541 2-Jun-2015
INBRX001-US-D1	US	Issued	14/700,105 6-Feb-2013	9,663,575 30-May-2017
INBRX001-AU	AU	Issued	2013217114 6-Feb-2013	2013217114 30-Mar-2017
INBRX001-BR	BR	Pending	1120140193312 6-Feb-2013	
INBRX001-CA	CA	Pending	2863834 6-Feb-2013	
INBRX001-CL	CL	Pending	20142086 6-Feb-2013	
INBRX001-CN	CN	Issued	2013800179000 6-Feb-2013	ZL201380017900.0 6/9/2020
INBRX001-CN-PCD	CN	Pending	202010418862.1 6-Feb-2013	
INBRX001-CO	CO	Issued	14171778 6-Feb-2013	14171778 6-Dec-2016
INBRX001-CR	CR	Pending	20140406 6-Feb-2013	
INBRX001-EA Validated in: RU	EA	Issued	201400875 6-Feb-2013	034778 19-Mar-2020
INBRX001-EC	EC	Pending	IEPI201416994 6-Feb-2013	
INBRX001-EG	EG	Pending	PCT12572014 6-Feb-2013	
INBRX001-EP Validated in: AL, AT, BA, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LU, LV, MC,	EP	Issued	137469649 6-Feb-2013	2812443 29-May-2019

ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR				
INBRX001-EP-D1	EP	Pending	19173042.3 6-Feb-2013	
INBRX001-ID	ID	Issued	P00201405270 6-Feb-2013	IDP00005873 15-May-2019
	ID	Pending	P00201803069 6-Feb-2013	
INBRX001-IL	IL	Pending	233934 6-Feb-2013	
INBRX001-IN	IN	Pending	6438CHENP2014 6-Feb-2013	
INBRX001-JP	JP	Issued	2014556634 6-Feb-2013	6273212 31-Jan-2018
INBRX001-KR	KR	Issued	1020147025286 6-Feb-2013	10-2100388 7-Apr-2020
INBRX001-KR-PCD	KR	Pending	10-2020-7009892 6-Feb-2013	
INBRX001-MX	MX	Issued	MX/a/2014/009427 6-Feb-2013	360772 15-Nov-2018
	MX	Pending	MX/a/2018/003882 6-Feb-2013	
INBRX001-MY	MY	Issued	PI2014002294 6-Feb-2013	MY-169341-A 21-Mar-2019
INBRX001-NZ	NZ	Issued	628314 6-Feb-2013	628314 28-Apr-2017
INBRX001-PH	PH	Issued	12014501758 6-Feb-2013	1/2014/501758 27-Nov-2018
INBRX001-SG	SG	Issued	11201404638S 6-Feb-2013	11201404638S 15-Feb-2017
INBRX001-SG-D1	SG	Pending	10201700160R 6-Feb-2013	
INBRX001-TH	TH	Pending	1401004515 6-Feb-2013	
INBRX001-UA	UA	Issued	a 2014 09709 6-Feb-2013	116772 10-May-2018
INBRX001-VN	VN	Pending	1201402973 6-Feb-2013	
INBRX001-ZA	ZA	Issued	201405864 6-Feb-2013	201405864 25-Nov-2015



INBRX001-HK	HK	Issued	151057469 6-Feb-2013	HK1205195 6/19/2020
	HK	Pending	42020008954.8 6-Feb-2013	

**NON-PLATELET DEPLETING AND NON-RED BLOOD CELL DEPLETING CD47 ANTIBODIES AND METHODS OF USE THEREOF**


Mofo (POON/POLIZZI/YOU)

Docket No.	Country	Status	Serial No./ Filing Date	Patent No./ Issue Date
	US	Pending	17/170,854 31-Aug-2015	
INBRX001-AU-2	AU	Issued	2013377886 6-Aug-2013	2013377886 14-Mar-2019
INBRX001-AU-2-D1	AU	Issued	2019200942 6-Aug-2013	2019200942 6-May-2021
INBRX001-BR-2	BR	Pending	1120150188516 6-Aug-2013	
INBRX001-CA-2	CA	Pending	2900468 6-Aug-2013	
INBRX001-CL-2	CL	Pending	201502203 6-Aug-2013	
INBRX001-CN-2	CN	Issued	2013800754093 6-Aug-2013	105101997 9-Nov-2018
INBRX001-EA-2	EA	Issued	201500818 6-Aug-2013	036963 1/20/2021
INBRX001-EC-2	EC	Pending	201538223 6-Aug-2013	
INBRX001-EG-2	EG	Pending	PCT12272015 6-Aug-2013	
INBRX001-EP-2	EP	Pending	138743836 6-Aug-2013	
INBRX001-ID-2	ID	Issued	P00201505447 6-Aug-2013	IDP000058855 16-May-2019
INBRX001-IL-2	IL	Issued	240390 6-Aug-2013	240390 1-Sep-2020
	IL	Pending	274566 6-Aug-2013	
INBRX001-IN-2	IN	Pending	4952CHENP2015 6-Aug-2013	
INBRX001-JP-2-D1	JP	Issued	2018-146460 6-Aug-2013	6726238 6/30/2020
INBRX001-KR-2	KR	Issued	1020157024103 6-Aug-2013	10-2170196 20-Oct-2020

INBRX001-KR-PCD[2]	KR	Issued	10-2020-7030070 6-Aug-2013	10-2276974 7-Jul-2021
INBRX001-MO-2	MO	Issued	J/003573 6-Aug-2013	J/003573 5-Jun-2019
INBRX001-MX-2	MX	Pending	MXa2015010115 6-Aug-2013	
INBRX001-MX-D1	MX	Pending	MX/a/2018/003882 6-Aug-2013	
	MX	Pending	MX/a/2021/008851 6-Aug-2013	
INBRX001-NI-2	NI	Pending	2015000103 6-Aug-2013	
INBRX001-NZ-2	NZ	Issued	710695 6-Aug-2013	710695 1-Sep-2020
INBRX001-PE-2	PE	Issued	16282015 6-Aug-2013	9897 2-Mar-2020
INBRX001-PH-2	PH	Pending	12015501729 6-Aug-2013	
INBRX001-TH-2	TH	Pending	1501004422 6-Aug-2013	
INBRX001-UA-2	UA	Pending	201508516 6-Aug-2013	
INBRX001-UA-2-D1	UA	Pending	a 2020 01337 6-Aug-2013	
INBRX001-VN-2	VN	Pending	1201503152 6-Aug-2013	
	VN	Pending	1-2021-03898 8/6/2013	
INBRX001-ZA-2	ZA	Issued	201505745 6-Aug-2013	2015/05745 26-Feb-2020
INBRX001-ZA-2-D1	ZA	Pending	2019/05292 6-Aug-2013	
INBRX001-HK-2	HK	Pending	161068857 6-Aug-2013	
INBRX001-SG-2-D1	SG	Pending	10201706383X 6-Aug-2013	

EXHIBIT C

Trademarks

Mark Type	Stylized Form (as applicable)	Application No. / Registration No.	Owner	Application/ Publication Dates	Jurisdiction
Service Mark		88/595545	Inhibrx, Inc.	8/28/19 (application filed) 1/7/20 (publication) 3/24/20 (registration)	US
Trademark	CONTRA-MAB	88/081271 / 6,029,997	Inhibrx, Inc.	1/7/19 (publication); 1/28/20 (Statement of Use Filed) 4/7/20 (Registration)	US
Trademark	CONTRA-MAB	37763803	Inhibrx, Inc.	11/27/19 (Publication) 2/28/20 (Registration)	China